Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Akero Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Akero Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harrison Seth Loring | Director | 0 | Dec 9, 2025 | 1 |
| Iwicki Mark T | Director | 0 | Dec 9, 2025 | 1 |
| Henderson Jane | Director | 0 | Dec 9, 2025 | 1 |
| Gangloff Scott A. | Chief Technology Officer | 0 | Dec 9, 2025 | 1 |
| Graham G. Walmsley | Director | 0 | Dec 9, 2025 | 2 |
| Cheng Andrew | President and CEO | 0 | Dec 9, 2025 | 5 |
| White William Richard | Chief Financial Officer | 0 | Dec 9, 2025 | 1 |
| Yale Catriona | Chief Development Officer | 0 | Dec 9, 2025 | 2 |
| Rolph Timothy | Chief Scientific Officer | 0 | Dec 9, 2025 | 4 |
| Young Jonathan | Chief Operating Officer | 0 | Dec 9, 2025 | 3 |
| Heyman Tomas J. | Director | 0 | Dec 9, 2025 | 1 |
| Xu Yuan | Director | 0 | Dec 9, 2025 | 1 |
| Judy Chou | Director | 0 | Dec 9, 2025 | 1 |
| Lamy Patrick | See Remarks | 0 | Dec 9, 2025 | 1 |
| Ezbon International Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Blue Horizon Enterprise Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Montrago Trustees Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Skorpios Trust | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 (view filing) | Sep 8 | 2 days | Rolph TimothyChief Scientific Officer | SSale | −12.5K | $44.17 | −$552.1K | −7.0%167.1K after | 2 lots10b5-1 |
| Sep 12, 2025 (view filing) | Sep 10-11 | 2 days | Cheng AndrewPresident and CEO | SSale | −31.8K | $43.23 | −$1.37M | −6.3%473.9K after | 4 lots10b5-1 |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Rolph TimothyChief Scientific Officer | SSale | −553 | $43.02 | −$23.8K | −0.3%166.6K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | White William RichardChief Financial Officer | SSale | −659 | $43.02 | −$28.4K | −1.1%57.8K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Yale CatrionaChief Development Officer | SSale | −659 | $43.02 | −$28.4K | −0.7%90.8K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Young JonathanChief Operating Officer | SSale | −586 | $43.02 | −$25.2K | −0.3%196.9K after | |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Young JonathanChief Operating Officer | SSale | −12.5K | $47.75 | −$596.9K | −6.0%196.9K after | 2 lots10b5-1 |
| Oct 9, 2025 (view filing) | Oct 7 | 2 days | Rolph TimothyChief Scientific Officer | SSale | −12.5K | $46.08 | −$576.0K | −7.0%166.6K after | 2 lots10b5-1 |
| Oct 14, 2025 (view filing) | Oct 10 | 4 days | Cheng AndrewPresident and CEO | SSale | −30.0K | $53.98 | −$1.62M | −5.4%526.1K after | 10b5-1 |